| Second Sight Medical Products develops, manufactures and markets implantable visual prosthetics that deliver artificial vision to blind individuals. Co.'s product, the Argus ® II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. RP is a hereditary disease that causes a progressive degeneration of the light-sensitive cells of the retina, which leads to visual impairment and blindness. The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision nor slow the progression of the disease. We show 26 historical shares outstanding datapoints in our EYES shares outstanding history coverage, used to compute EYES market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EYES market cap history over the course of time is important for investors
interested in comparing EYES's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EYES versus a peer is one thing; comparing
EYES market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EYES can fluctuate over the course of history.
With this page we aim to empower investors researching EYES by allowing them to research the EYES market cap history.